Hepatocellular carcinoma (HCC) tissue possessed a stronger metabolic reprogramming capacity for lenvatinib compared with liver tissue during the combination theapy based on anti‐PD1 antibody plus lenvatinib, as reflected by the activation of the CCL5/CCR5/CYP1A1 pathway. Here, CCL5 is linked to hepatocellular carcinoma.